



Bone marrow (BM) necrosis is a rare clinicopathological entity. The 
most common underlying diseases are leukemia and lymphoma, 
particularly high-grade lymphoma [1, 2].
Waldenström’s macroglobulinemia (WM) is defined as BM 
infiltration primarily by lymphoplasmacytic lymphoma (LPL) along 
with immunoglobulin M (IgM) monoclonal gammopathy. LPL is 
a B-cell neoplasm composed of small lymphocytes, plasmacytoid 
lymphocytes, and plasma cells, involving the BM, lymph nodes (LNs), 
and the spleen, which does not fulfill the criteria for any other B-cell 
neoplasm with plasmacytic differentiation, defined by the World Health 
Organization (WHO) in 2008.
WM is an indolent mature B-cell neoplasm, and the survival outcomes 
of the patients have improved. However, it may occasionally transform 
to histologically more aggressive lymphoma, such as diffuse large 
B-cell lymphoma (DLBCL). Transformation to DLBCL is associated 
with poor prognosis [3–6].
Here, we report a rare case of WM accompanied by massive BM 
necrosis. The original WM seemed to be in a stable state without 
increase of serum IgM levels, change in splenomegaly status, or LN 
swellings.
Case presentation
A mid-60s patient was admitted to the hospital due to lumbago and 
severe pain of the extremities. The patient had been diagnosed with 
WM 9 years ago, when the laboratory findings had revealed relatively 
normal levels of markers, including alkaline phosphatase (ALP), lactate 
dehydrogenase (LDH), and C-reactive protein (CRP), except for reduced 
hemoglobin level (4.6 g/dL) and platelet count (53 × 109/L), as well 
as elevated levels of soluble interleukin (IL)-2 receptor (sIL-2R) (5720 U/ 
mL). IgM-λ M protein was detected, with elevated IgM (6130 mg/dL) 
and relatively normal IgG and IgA levels (803 mg/dL and 136 mg/dL, 
respectively). BM examination revealed hypercellular marrow (nuclear 
cell count was 24.0 × 104/mm3) with 0/mm3 megakaryocytes. Lymphoid 
cells were increased (80.8%) and were diffusely infiltrated into residual 
normal BM cells. The cells were small-to-medium-sized ones, 
with a high nucleus-to-cytoplasm (N/C) ratio and round-to-oval-shaped 
nuclei. An immunohistochemical study and flow cytometric (FCM) 
analysis demonstrated that the tumor cells were positive for cluster of 
differentiation (CD)19, CD20, CD79a, CD38, CD138, IgM, and λ, as well 
as being negative for CD3, CD4, CD5, CD8, CD10, CD23, cyclinD1, 
and k. Some cells had Dutcher bodies, and mast cells were increased. 
Chromosomal analysis demonstrated a normal karyotype.
Upon administration of steroids and three lines of chemotherapy 
with two to six courses of fludarabine, WM remained in a stable 
state for a long period of time (Fig. 1). Administration of prednisolone 
(PSL) (45 mg/day orally, then tapered) ameliorated the patient’s 
symptoms and anemia for an extended duration. However, 32 months 
and 72 months later, anemia and elevation of IgM-M protein were 
exacerbated. The patient received two (FLU-1 in Figure 1) and 
six (FLU-2 in Figure 1) courses of chemotherapy with fludarabine 
(40 mg/day orally for 5 days), resulting in amelioration of hemoglobin 
(7.2 g/dL to 9.7 g/dL, 7.2 g/dL to 10.4 g/dL, respectively), platelet count 
(79 × 109/L to 99 × 109/L, 61 × 109/L to76 × 109/L, respectively), sIL-2R 
(4896 U/mL to 4408 U/mL, 6129 U/mL to 5158 U/mL, respectively), 
and IgM (6960 mg/dL to 5200 mg/dL, 9230 mg/dL to 4055 mg/dL, 
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respectively). Moreover, 99 months later (22 months after the patient’s 
second period of treatment with fludarabine [FLU-2 in Figure 1]), 
anemia and elevation of IgM-M protein had gradually worsened. The 
patient received readministration of five courses of fludarabine (FLU-
3 in Figure 1), which reduced the serum IgM levels (5120 mg/dL to 
2298 mg/dL); however, anemia remained progressive (8.0 g/dL to 6.1 
g/dL).
At the present admission, laboratory findings revealed a normal 
white blood cell (WBC) count of 4.66 × 109/L without abnormal cells, 
reduced hemoglobin (6.0 g/dL), and platelet count of 20 × 109/L. 
Serum chemistry revealed elevated levels of ALP (713 U/L), LDH 
(1698 U/L), and CRP (14.9 mg/dL). Although IgM level was stable 
(2178 mg/dL), sIL-2R was elevated (25800 U/mL).
18F-Fluorodeoxyglucose positron emission tomography (PET)/ 
computed tomography (CT) findings revealed very strong 
accumulation in multiple bones, without prominent swelling of LNs. 
Spleen was enlarged; however, only a fine incorporation of 
18F-fluorodeoxyglucose was observed, and the size was not increased 
throughout the course (Fig. 2 A and B). As the patient was suffering 
from severe bone pain with elevated levels of serum ALP and 
LDH and because strong incorporation of 18F-fluorodeoxyglucose in 
multiple bones was observed on PET/CT, multiple cancer metastases 
to the bones was suggested.
BM biopsy demonstrated extensive necrosis (Fig. 3 A and B). In 
addition to the necrotic tissue, small-to-medium-sized WM cells and 
large lymphoid cells with high N/C ratio were also observed (Figure 3 C 
and D). Normal BM cells were rarely observed. Immunohistochemical 
study demonstrated that both the small-to-medium-sized cells 
and  the larger cells were CD20+ (Fig. 3 E). Some larger cells were 
also CD5+ (Fig. 3 F). In situ hybridization test for Epstein–Barr 
virus-encoded RNA was negative.
FCM analysis showed that the smaller cells were positive for CD19, 
CD20, IgD, and λ; partially positive for CD27, CD38, CD43, CD138, 
and IgM; and negative for CD2, CD3, CD4, CD5, CD8, CD10, 
CD11c, CD16, CD23, CD25, CD30, CD34, CD56, and k (Fig. 3 G). 
On the other hand, the large cells were positive for CD5, CD19, 
CD20, and λ and were negative for CD43, CD138, IgD, and IgM 
(Fig. 3 H). Southern blot analysis for the Ig heavy chain (IgH) 
gene revealed rearranged bands, suggesting clonal proliferation. 
Chromosomal analysis revealed complex abnormality: 47,XY, add(1)
(q32), add(2)(p11.2), add(3)(q21), der(3)add(3)(p13)add(3)(q27), 
del(7) (q22),der(8)add(8)(p11.2)add(8)(q24), add(12)(q13), add(14)
(q32), -15, +del(16)(q?), +mar1 in 19/20 cells.
The patient was diagnosed as having CD5-positive DLBCL, 
which was transformed from CD5-negative WM, and received 
chemotherapy (48 mg of pirarubicin, 1.6 mg of vincristine sulfate, 
800 mg of cyclophosphamide, and 45 mg of PSL for 5 days), which 
was followed by only transient resolution of the patient’s symptoms. 
The patient died due to the progression of DLBCL 7 weeks after the 
present admission, 110 months after the first visit to the hospital.
Discussion
WM is usually an indolent and slowly progressive disease, and 
the overall survival of patients has improved over the past decade 
[4]. WM may transform to DLBCL rarely [3–6]. The interval 
Fig. 1. Clinical course of the patient
Administration of PSL (45 mg/day, then tapered) ameliorated the patient’s symptoms and anemia, and the patient remained in 
a stable state for a long period of time. However, 32 months and 72 months later, anemia and elevation of IgM-M protein were ex- 
acerbated. The patient underwent two (FLU-1) and six (FLU-2) courses of chemotherapy with fludarabine (40 mg/day for 5 days), 
respectively, resulting in amelioration of the symptoms and stabilization. The patient underwent readministration of five courses of 
fludarabine (FLU-3), which reduced the serum IgM levels; however, anemia remained progressive.
Abbreviations: Hb: hemoglobin, IgM: immunoglobulin M, LDH: lactate dehydrogenase, PSL: prednisolone, FLU: fludarabine, 
THP-COP: pirarubicin, vincristine sulfate, cyclophosphamide, and PSL
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from the diagnosis of WM to transformation to DLBCL is reported 
to be 10-128 months [3, 4, 6]. Most patients have generalized 
lymphadenopathy and hepatosplenomegaly with B symptoms at the 
onset of DLBCL. The interval between the occurrence of WM 
and DLBCL in the present case was approximately 107 months. The 
patient’s symptoms, images, and laboratory findings at the onset of 
DLBCL, such as severe bone pain, elevated levels of serum ALP and 
LDH, and strong incorporation of 18F-fluorodeoxyglucose in multiple 
bones, resembled bone metastasis. Increase in size of the spleen or 
prominently enlarged LNs were not observed.
There are two types of DLBCL transformed from WM: one is clonally 
identical to the original WM, and the other is different from the 
co-occurring WM [5]. In the BM of the present patient, clusters of 
DLBCL were observed within the nodular proliferation of WM cells, 
and these were not independently proliferating, suggesting that 
the DLBCL had been transformed from WM. Whether the DLBCL 
and WM were clonally identical could not be established, due to 
the inability to analyze the third complementarity determining region 
(CDR3) sequence in the IgH gene. However, FCM analysis showed 
that both the smaller and the larger cells were positive for λ, and 
Southern blot analysis for the IgH gene revealed rearranged bands, 
suggesting clonal proliferation.
WM cases express IgM and pan-B markers, such as CD19 and CD20, 
and are usually negative for CD5, CD10, and CD23 [7]. In the present 
case, WM cells had been negative for CD5; however, DLBCL cells 
later demonstrated CD5 positivity. It is well known that CD5-positive 
DLBCL cases show poorer prognosis than CD5-negative DLBCL 
cases [8]. Transformation of CD5-negative low-grade lymphoma to 
CD5-positive DLBCL is very rare. Particularly, to the best of our 
knowledge, this is the first report of CD5-positive DLBCL transformed 
from CD5-negative WM. The transformed DLBCL cells were negative 
for CD43, CD138, IgD, and IgM, with the original WM cells being 
positive for the same, and showed complex chromosomal abnormality, 
suggesting an immature aggressive type.
In the present case, first and second chemotherapy with fludarabine 
ameliorated both the patient’s anemia and M-proteinemia. On the 
other hand, although the third administration of fludarabine was 
able to reduce the serum IgM levels, anemia was progressive, 
suggesting that the BM was gradually being occupied by non-Ig- 
producing immature lymphoma cells during the third administration 
of fludarabine. Several months later, highly progressive development 
of DLBCL was readily apparent, accompanied by BM necrosis.
In our patient, transformation to DLBCL occurred shortly after 
the third administration of fludarabine. Immune suppression by 
purine analogues may lead to aggressive transformation because of 
defects in tumor surveillance [9]. The potential relationship between 
transformation to high-grade lymphoma and treatment with purine 
analogues has been controversial [10, 11]. Moreover, histological 
transformation could occur not only in patients who received 
chemotherapy with alkylating agents and/or purine analogues but 
also in treatment-naïve patients [4].
Fig. 2. Images of the patient
(A) FDG PET/CT findings at the patient’s first visit to the hospital 9 years ago demonstrated marked splenomegaly without promi-
nent swelling of LNs. No masses or necrosis was observed in the spleen. Only fine FDG accumulation was observed in the enlarged
spleen.
(B) FDG-PET/CT findings at the present admission revealed very strong accumulation of FDG in multiple bones. Only fine FDG ac-
cumulation was observed in enlarged spleen.
Abbreviations: CT: computed tomography, FDG: 18F-fluorodeoxyglucose, LN: lymph node, PET: positron emission tomography
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Fig. 3. Histological, immunohistochemical, and flow cytometric analysis of the BM. (A-F) Histological and immunohistochemical 
findings of the BM
(A, B, D) In a low-power field of BM biopsy (A) and clot section (B, D), massive amorphous granular material with degenerated cells 
was observed. BM was hypercellular and occupied by small-to-large-sized lymphoid cells. Normal BM components were rarely 
observed (HE: ×10).
(C) In a high-power field, in addition to the small-to-medium-sized cells, many larger cells with high N/C ratio also demonstrated 
proliferation. Some small-to-medium-sized cells had Dutcher bodies. Hemophagocytosis was also observed (HE: ×40).
(E) Both small-to-medium-sized cells and larger cells were CD20+ (×10). (F) Some larger cells were also CD5+ (×10).
(G, H) Flow cytometric analysis of BM cells.
(G) The smaller cells were CD19+, CD20+, IgD+, and λ positive. Cells were partially positive for IgM, CD43, CD38, and CD138 but
negative for CD5 and CD10.
(H) The larger cells were positive for CD19, CD20, CD5, and λ and were partially positive for CD38. These cells were negative for
IgD, IgM, CD10, CD43, and CD138.




On the other hand, some antineoplastic drugs such as fludarabine 
may cause BM necrosis [12]. However, in the present case, extremely 
elevated sIL-2R level was observed when the patient suffered from 
BM necrosis, suggested that the rapidly progressive DLBCL was the 
underlying cause of BM necrosis.
WM is incurable with currently available chemotherapy, and there 
is no standard therapy. Alkylating agents and purine analogues are 
the most commonly used agents. Our case was an indolent 
outpatient and preferred oral administration of fludarabine [11, 13]. 
Recently, however, combination chemotherapy regimens containing 
rituximab are recommended for first-line therapy [14]. Moreover, 
the most common therapy used to treat DLBCL transformed from 
WM is the combination consisting of rituximab, cyclophosphamide, 
hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), 
vincristine (Oncovin), and prednisone (R-CHOP) [4]. Unfortunately, 
in our patient, rituximab could not be administered due to the need to 
avoid tumor lysis syndrome because of the patient’s extremely high 
tumor burden. The patient died due to the progression of DLBCL, 
which is the most common cause of death in WM patients with 
histological transformation [4]. In summary, we demonstrated a rare 
CD5-positive DLBCL transformed from CD5-negative WM. The 
DLBCL was highly aggressive and accompanied by BM necrosis. 
Clinicians should be aware of the co-occurrence of non-Ig-producing 
aggressive lymphoma, when inexplicable anemia is observed even 
with good response of low-grade lymphoma to chemotherapy, in 
addition to paying attention to accompanying massive BM necrosis, 
which mimics multiple cancer metastases to the bone.
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